Trastuzumab Emtansine ‘Standard of Care’ for Advanced HER2-Positive Breast Cancer

Treatment of advanced HER2-positive breast cancer should include trastuzumab emtansine after initial taxane and HER2-directed treatment fails. 

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.